Introduction
Leading causes of hospitalization in patients with cirrhosis include hepatic encephalopathy, upper gastrointestinal bleeding, bacterial infections and rapid accumulation of ascites; collectively referred to as acute decompensation (AD) [1] .
During AD episodes a proportion of patients newly develop liver and/or extrahepatic organ failure(s), a distinct clinical entity defined as acute-on-chronic liver failure (ACLF) [1] . ACLF has recently gained great interest for several reasons. The syndrome is associated with high short-term mortality, but precipitating factors and the exact pathogenetic processes have not yet been completely identified [2] . Bacterial infections clearly have an important role [3] . Various clinical factors have been established as predictors of short-term mortality in patients with bacterial infection [4] . Biomarkers identifying relevant pathophysiological pathways in patients with infection potentially may add value to understanding and managing this condition [5] .
Monocytes and macrophages are important cellular components of the innate immune system. Resident macrophages of the liver, Kupffer cells, have a central role in the orchestration of pro-and anti-inflammatory processes and have been studied extensively in chronic liver diseases [6] . During inflammation the haemoglobinhaptoglobin scavenger receptor, CD163 is cleaved from the surface of macrophages.
This soluble form (sCD163) is thereafter detectable in the systemic circulation and regarded as a marker of macrophage activation [7, 8] . Binding and internalization of the haemoglobin-haptoglobin complex is a well described function of this receptor, but several other functions have also been attributed to CD163 [8] . CD163 is expressed on M2-type (pro-resolution, anti-inflammatory) liver macrophages in the presence of local microenvironmental anti-inflammatory signals such as interleukin (IL)-10 [9,10]. Accordingly, high serum level of sCD163 has been considered as a representative marker of the anti-inflammatory response in a number of clinical studies [11] [12] [13] [14] Recently, monocytes and macrophages of anti-inflammatory properties were highlighted in the pathogenesis of AD and development of organ failure in cirrhosis [15, 16] .
Increased serum sCD163 level were found in non-cirrhotic patients during bacterial infection and even higher levels in sepsis. An association between increased sCD163 level and reduced survival has also been reported [11, 12, 17, 18] . In cirrhosis, increased sCD163 level was reported in patients with significant portal hypertension or advanced disease stage [19] [20] [21] . It was also demonstrated that the sources of sCD163 were the macrophages of the liver [20] . Moreover, in a study of Waidmann et al. [22] , sCD163 level was found to be a prognostic marker of overall survival and the development of variceal bleeding. Development of other long-term complications (i.e. hepatic encephalopathy, ascites and bacterial infections) of cirrhosis in relation to sCD163 level however, has not been yet evaluated. In addition no data are available regarding the significance of macrophage activation represented by sCD163 serum level during bacterial infection and/or other AD episodes of cirrhosis.
The aim of the present study was to investigate the clinical importance of sCD163 in a large referral patient cohort with cirrhosis. The primary aim was to assess the association between serum sCD163 level and the disease specific characteristics (disease severity, portal hypertension or presence and type of the acute decompensation event). Secondary aim was to evaluate whether sCD163 level is able to predict poor disease outcomes in cirrhosis. (1) In stable outpatients we evaluated the advent of decompensation events (ascites formation, hepatic encephalopathy, variceal bleeding, and/or bacterial infections) and long-term mortality. (2) In patients with acute decompensation we evaluated short-term mortality with careful distinction of bacterial infections.
Patients and methods

Patient population
We performed a cohort study among adult patients with established diagnosis of cirrhosis of different etiologies in a tertiary care referral center of Hungary (Division of Gastroenterology Department of Internal Medicine, Clinical Center, University of Debrecen). This cohort was reported in previous serological studies of our group [23, 24] . Between May 1, 2006 and December 31, 2010, patients were included consecutively from the outpatient clinic during regular or extraordinary follow-up visits and also from the inpatient ward due to hospitalization with an AD episode. The exclusion criteria were (1) if the patient or his/her legal surrogate declined to participate in the study and did not sign the informed consent or (2) if the patient was sent just for specialist consultation, and followed-up regularly elsewhere. For present study serum samples of 378 patients (193 outpatients and 185 hospitalized subjects due to an AD episode) were available.
Clinical characteristics of the patients at inclusion are presented in Table 1 .
Diagnosis of cirrhosis was based on clinical, biochemical, imaging and when available, histological data. Blood samples, routine laboratory data and detailed clinical phenotype were captured at inclusion. Clinical data were determined by in-depth review of the patients' medical records using a structured interview. Medical records that documented age at diagnosis, etiology, presence of esophageal varices, history of previous AD episode(s), presence of hepatocellular carcinoma, extrahepatic co-morbidities (myocardial infarction, congestive heart failure, peripheral arterial disease, cerebrovascular disease, chronic pulmonary disease, chronic renal failure, diabetes mellitus, extra-hepatic malignant disease) and cirrhosis-related medication were retrospectively analyzed for the period prior to the observational follow-up study.
Indications for non-selective beta-blockers either in primary or secondary prophylaxis of variceal bleeding were considered on the recommendation of current guidelines [25] .
Indications for proton pump inhibitors were gastroesophageal reflux disease, erosive gastritis, peptic ulcer disease or treatment for Helicobater pylori infection [26] . At enrolment, disease severity assessed by liver-oriented scores (Child-Pugh and MELD) were determined. If present, the type of the AD episode was established. Acute decompensation was defined by one or any combination of the following events:
development of large ascites, hepatic encephalopathy, gastrointestinal hemorrhage and bacterial infection. Development of large ascites was defined by grade II/III ascites, according to the International Club of Ascites [27] , patients with refractory ascites were not included. Acute hepatic encephalopathy was defined by acute worsening of mental status in a previously conscious patient, without the evidence of acute neurological disease [28] . Acute gastrointestinal bleeding was diagnosed by esophago-gastroduodenoscopy, and was attributed to acute variceal bleeding according to conventional criteria [29] . Presence of systemic bacterial infection was carefully established by compatible clinical symptoms, laboratory data (leucocyte count, high-sensitivity C- Further characterization of bacterial infections was done on the basis of conventional criteria [30] [31] [32] [33] . Additionally, during AD events presence of ACLF and its grade was also assessed, although only retrospectively after the new definition of ACLF became available in September, 2013 [1] .
The control group consisted of 150 age and gender matched healthy blood donors (male/female: 72/78, age: 51.5±16.9 years).
Phenotypical characterization of patients during follow-up
Patients were enrolled into an observational follow-up study, where the attending gastroenterologist registered laboratory data, imaging and endoscopic findings, disease severity, medical treatment, date and type of disease specific complications during regular and extraordinary outpatient follow-up visits and inpatient stays. In Hungary, a regular outpatient follow-up visit is usually scheduled for every 3 months at a specialized gastroenterology center for patients with decompensated cirrhosis (a followup between 1-3 months may be scheduled if dictated by disease severity or presence of certain disease specific complications) and for up to 6 months for patients with cirrhosis but without prior episode of AD. The follow-up period lasted 5 years, or death/loss of follow-up. The median follow up was 661 days (IQR: 104-1563).
Collected data were transferred and stored in a database. At the end of the study period, December 31, 2013, all clinical data were extracted for further analysis. Development of complications, (i.e. occurrence of ascites formation, variceal bleeding, hepatic encephalopathy, clinically significant bacterial infection or death were defined as adverse outcomes.
Serological analysis
Blood samples were obtained at enrolment from each patient and were frozen at -70°C until testing, 2013 May. Very high stability of the molecule over time and different conditions were reported previously. sCD163 was resistant to repeated freezing and thawing. [8, 34] . Serum level of sCD163 were determined by a solid-phase enzymelinked immunoassay, according to the manufacturer's instructions (IQProducts, Groningen, Netherlands), in a blinded fashion. Samples were measured in duplicates on the same plate, and the mean values was used. Between runs, coefficients of variation (CV) were 8%. The limit of detection was 0.23 ng/mL. sCD14 evaluation was performed previously [23] , using ELISA (Quantikine, R&D Systems, Minneapolis, MN).
Serological assays were performed at the Department of Laboratory Medicine in a blinded fashion by a qualified analyst (E.T.) without prior knowledge of the patient's clinical information.
Ethical considerations
The study protocol was approved by Regional and Institutional Research Ethics 
Statistical analysis
Variables were tested for normality using Shapiro Wilk's W test. Continuous variables A 2-sided probability value of <0.05 was considered to be statistically significant.
Results
Serum values of sCD163 ranged from 279 to 28818 ng/mL in the total patient population and was significantly higher compared to healthy subjects ( 
sCD163 level in outpatients
In a total of 193 outpatient subjects, sCD163 level was not associated with the presence of portal hypertension characterized by the presence of ascites (Fig. 1A) , prior episodes of variceal bleeding or presence of esophageal varices (Fig. 1B) .
We then analyzed the association between sCD163 level and poor disease outcomes (advent of AD events and liver-related death). (Table 2B) .
sCD163 level in patients with acute decompensation episode
In a total of 185 patients with acute decompensation episode, sCD163 level was significantly higher in patients with AD episode compared to outpatients, but only in the presence of bacterial infection ( Fig. 2A) . We were also able to confirm this association intra-individually. In a subgroup of stable outpatients (n=33), during a subsequent AD episode with an ongoing bacterial infection, sCD163 level showed a significant increase In the univariate Cox-regression analysis, patients with high sCD163 level (>7000 ng/mL) and bacterial infection had significantly higher risk of short-term mortality when compared to those with low sCD163 level (HR: 3.04, [95%CI: 1.38-6.71], p=0.006). Using this derived cut-off in patients without bacterial infection, however, elevated level of sCD163 was not associated with short-term mortality. Kaplan-Meier survival curves for subgroups of AD patients with or without bacterial infection is demonstrated in Figure 3 . Of the clinical factors, disease etiology and presence of comorbidities but not the patients' age, gender or the presence of ascites and prior AD episode within 6 months were significantly associated with short-term mortality.
Furthermore, disease severity depicted by MELD score and increased level of markers related to pro-inflammatory response (CRP and leukocyte count) were also significantly associated with short-term mortality in patients with bacterial infections (Table 3) .
Multivariate Cox regression analysis indicated that sCD163 level did remain an independent predictor of short-term mortality during bacterial infection (HR: 2.96, [95%CI: 1.27-6.95], p=0.012), next to presence of co-morbidities, disease etiology, high MELD score (> 21) and leukocyte count, whereas CRP lost its significance ( Table 3) .
To visualize the impact of sCD163 level on short-term mortality, we plotted the estimated event rates according to leukocyte count as a continuous variable in the four different subgroups of patients (Fig. 4) . In the case of a high level of sCD163, the 28-day mortality rate is increased both in groups with high or low MELD score at any given value of leukocyte count.
Discussion
The soluble form of CD163 scavenger receptor has long been known as a surrogate parameter of macrophage activation in various diseases [8] , and has a good correlation with other soluble macrophage activation markers, such as soluble urokinase plasminogen activator receptor (suPAR), soluble mannose receptor [12, 36, 37] , but does not correlate with sCD14 [38] , that is also shed from macrophages. In the present study however sCD163 had a significant but inverse correlation with sCD14.
Recently sCD163 has emerged as a promising novel marker in cirrhosis [22] .
Enhanced formation of sCD163 is a well-known characteristic of cirrhosis and is consistently associated with advanced disease stage in the few currently available clinical studies [19, 20] . Nonetheless, changes in the serum level of sCD163 during various types of AD episodes are less known and there are still many questions regarding its predictive role in the development of disease specific complications during the disease course. This is the rationale for the present study in which we comprehensively assessed the utility of serum sCD163 level in a large prospective cirrhotic patient cohort with a careful assessment of acute deterioration.
First, we evaluated the association between sCD163 level and the disease specific characteristics of the cirrhotic patients. We were able to confirm previous findings that in cirrhosis, sCD163 level does increase up to the three-fold higher than the value observed in control subjects and displays a gradual increase according to disease severity [19, 20] . Median sCD163 values in our cohort corresponded to those reported previously.
Association of sCD163 level to clinically significant portal hypertension was extensively assessed in cirrhosis previously, but yielded somewhat conflicting results. sCD163 level was positively correlated to portal hypertension assessed by invasive hemodynamic measurement [20] . Interestingly, alleviation of portal pressure by TIPS insertion was not followed by a significant drop in sCD163 level. A later study by the same Danish group [19] , revealed that significant correlation between sCD163 level and portal hypertension was only present in early, but not in advanced disease stages.
Contrary to invasive hemodynamic studies, sCD163 level did not differ according to presence or absence of esophageal varices or in acute bleeding [22] . Correspondingly, we also found that the sCD163 level was not associated with the presence of varices, prior or recent variceal bleeding episodes.
In the present study, sCD163 level was neither associated with poor disease outcomes in outpatients, nor with the development of disease-specific complications or the overall survival during follow-up. In cirrhosis, one single prospective study [22] assessed the predictive value of sCD163 level during the disease course, and reported that increased sCD163 level was an independent predictor of variceal bleeding and long-term mortality. That large consecutive single center cohort (n=244) comprised both outpatients and subjects hospitalized due to acute complications of cirrhosis. Thirty percent of their patients had a concomitant bacterial infection. Regarding clinical characteristics, a comparable patient population was included in our study, but a different approach was applied for the evaluation. Outpatients and patients with ongoing AD episodes were not included in one single study group, as in the research of Waidmann et al., but were considered as two distinct patient populations for several reasons. On the one hand, infectious episodes represent particularly important causes of progression of liver failure and development of liver-related complications in patients with cirrhosis [5] . Moreover, regardless of the severity of hepatic insufficiency, development of bacterial infection significantly increases mortality rate. In-hospital mortality of cirrhotic patients with infection is more than twice that of patients without infection [39] . On the other hand, sCD163 level increases during bacterial infections both in non-cirrhotic [11, 12] and cirrhotic [22] demonstrated significantly higher level of sCD163 in cirrhotic patients (n=79) with bacterial infections. However, in their paper it was also stated that the sCD163 level remained constant for several weeks and was not substantially affected by acute bacterial infections during sequential examination of a small group of patients (n=7). As for our cohort, we have shown that sCD163 is increased in patients with bacterial infection. We were able to confirm this association intra-individual as well as in a larger group of patients (n=33). Furthermore we have also shown that the presence of bacterial infection is the only factor that significantly influences the level of sCD163 during AD episodes. Interestingly, we found that the more severe the infection -defined by the presence of organ failure(s) -the higher the level of sCD163. This finding is in agreement with the results of the early study of Møller et al. [12] , in which sCD163 level was significantly higher during pneumococcal infection in cases complicated by organ failure in non-cirrhotic patients.
Here, we have shown for the first time [40] , that in cirrhosis the 28-day mortality was associated with increased sCD163 level (>7000 ng/mL) during bacterial infection.
Almost half of the patients with high level of sCD163 died compared to only 16% of patients with low level of sCD163. Short-term mortality risk associated with high sCD163 level (HR: 2.96) was very similar to the risk (HR: 3.05) associated with high suPAR level, another macrophage activation marker, reported in the study of Zimmermann et al. [41] . In our study sCD163 was an independent risk factor regardless of the disease severity and the extent of the pro-inflammatory response, represented by MELD score, CRP and leukocyte count, respectively. This finding is consistent with the observations that excessive anti-inflammatory response, represented by interleukin-10, interleukin-6 [42] or soluble tumor necrosis factor-α receptor (sTNFR) [43] and decreased monocyte HLA-DR expression [15] has a significant negative impact on survival in cirrhosis, as recently reviewed by Albillos et al. [44] . Interestingly various markers of the anti-inflammatory response had similar short-term mortality risk than sCD163 in our study. monocytes in vitro [16] .
During bacterial infection, accurate and early selection of the most vulnerable patients requiring intensive care and monitoring is of importance in clinical practice [5] .
From a pathophysiological point of view including a representative biomarker of the altered anti-inflammatory pathway into a predictive model makes sense. sCD163 might be a promising candidate for this purpose based on our findings. The present study, however, had an exploratory purpose. The relatively low sample size of patients with bacterial infection (n=99), and the single centre design did not allow us to satisfy the above mentioned, but so far unmet need. Recently predictive models of cirrhosis and short-term survival were developed in multicenter cohorts with much larger patient populations [4, 45] . Our single-point measurement approach did not allow for evaluating the potential importance of sCD163 kinetics, which is another limitation of our study.
To conclude, the findings of our referral cohort study of patients with cirrhosis indicate that serum sCD163 levels are not useful in outpatients for predicting complications or death; however, it may be a useful marker for the short-term stratification of patients with bacterial infection. In this patient population, high sCD163 level is a risk factor for the short-term mortality independently from both the disease severity and the extent of the pro-inflammatory response. These results further highlight the deleterious effect of the excessive anti-inflammatory response during bacterial infection. 
